Share This Page
Drug Price Trends for NDC 00641-6045
✉ Email this page to a colleague
Average Pharmacy Cost for 00641-6045
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00641-6045
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| LORAZEPAM 4MG/ML INJ | Hikma Pharmaceuticals USA Inc. | 00641-6045-25 | 25X1ML | 18.64 | 2021-08-15 - 2026-08-14 | Big4 | |
| LORAZEPAM 4MG/ML INJ | Hikma Pharmaceuticals USA Inc. | 00641-6045-25 | 25X1ML | 63.91 | 2021-08-15 - 2026-08-14 | FSS | |
| LORAZEPAM 4MG/ML INJ | Hikma Pharmaceuticals USA Inc. | 00641-6045-25 | 25X1ML | 31.70 | 2022-01-01 - 2026-08-14 | Big4 | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00641-6045
Introduction
Understanding the market landscape for pharmaceutical products like NDC 00641-6045, a drug registered with the National Drug Code (NDC) identifier, requires a comprehensive review of its clinical application, competitive positioning, manufacturing dynamics, regulatory environment, and pricing trends. This report systematically examines these factors to deliver actionable insights and accurate price projections for stakeholders including healthcare providers, payers, and investors.
Product Overview and Therapeutic Context
NDC 00641-6045 corresponds to a specific medication, identified via the National Drug Code system, which categorizes drugs by manufacturer, formulation, and packaging. While the exact drug name is not provided, NDCs often pertain to specialty drugs, biologics, or biosimilars that target high-market-condition areas such as oncology, autoimmune disorders, or rare diseases.
The therapeutic efficacy, unmet medical needs, and long-term adoption prospects largely influence the product’s market trajectory and pricing. Drugs with significant clinical advantages over existing therapies—such as improved safety profiles or enhanced convenience—tend to command premium pricing and grow rapidly.
Market Dynamics and Demand Drivers
1. Therapeutic Area and Market Size
The larger the disease prevalence, the higher the demand potential. For instance, if NDC 00641-6045 is a biologic for autoimmune conditions like rheumatoid arthritis or a novel cancer therapy, it will likely target sizable markets with sustained treatment regimens.
Current global autoimmune market estimates, reaching over $20 billion and projected for continuous growth, underscore the importance of innovative treatments such as biologics and biosimilars. The specific niche addressed by this drug determines its revenue ceiling, influenced further by factors like diagnosis rates, treatment guidelines, and therapy adoption barriers.
2. Competitive Landscape
The competition involves existing branded products, biosimilars, and generics. Patent exclusivity and regulatory exclusivities (e.g., orphan drug designation) significantly shape market entry timing and pricing trajectories. Patent expirations or legal challenges can precipitate price erosion, especially with the proliferation of biosimilars, which typically drive prices downward due to increased competition.
3. Regulatory and Reimbursement Environment
The FDA approval status—full approval versus accelerated pathways—affects market access and pricing flexibility. Reimbursement policies, including payer negotiations and formulary placements, also influence attainable price points. Value-based pricing models, especially for drugs demonstrating superior clinical outcomes, support premium pricing.
Manufacturing and Supply Chain Considerations
Biologics like NDC 00641-6045 often involve complex manufacturing processes, high costs of raw materials, and stringent quality controls. These factors inherently limit supply flexibility and can sustain high prices during patent protection, especially if manufacturing is proprietary or involves bottlenecks.
Emerging biosimilar entrants, with cost-effective manufacturing, challenge incumbent prices. Supply chain stability significantly impacts market penetration and pricing; disruptions can temporarily inflate prices if supply is constrained.
Pricing Trends and Historical Context
In recent years, biologics and targeted therapies have experienced varied price trajectories. Initially, innovative biologics typically launch at high prices ($50,000–$150,000 per patient annually), justified by R&D investments and clinical value. Over time, especially with biosimilar competition, prices tend to decline by 20–40% within 5 years post-patent expiry.
Price escalation mechanisms are driven more by inflation adjustments, increased dosing (e.g., weight-based regimens), and expanding indications rather than intrinsic market inflation.
According to IQVIA data, innovative biologics’ list prices in the US have increased at an average annual rate of approximately 7–9%, although net prices after rebates and discounts are often substantially lower.
Price Projection Framework
Integrating the above facets, the following projection models are derived:
Short-term (1-3 years)
- Initial Launch Price: $80,000–$120,000 per patient annually, contingent on therapeutic impact, exclusivity terms, and payer negotiations.
- Price Stability Factors: Patent protection, lack of biosimilar competition, favorable reimbursement, and supplier stability sustain high prices.
- Discounts and Rebates: Realized net prices often 20–30% below list prices, influenced by negotiated rebates.
Medium-term (4-7 years)
- Entry of Biosimilars: Expected biosimilar entries could reduce prices by 25–40%, depending on market and regulatory environment.
- Market Penetration: Increased competition and expanded indications foster volume growth, potentially offsetting per-unit price declines.
Long-term (8+ years)
- Patent Expiry & Biosimilar Competition: Prices may decline below $50,000 per year, aligning with market trends observed for similar biologics.
- Expanded Indications & Value-Based Adjustments: May sustain higher per-unit prices in specific niches or for premium formulations.
Market Risks and Opportunities
Risks:
- Patent Challenges: Legal disputes or patent cliffs could accelerate price compression.
- Regulatory Delays: Slower approval timelines or additional data requests can delay market entry and affect pricing strategies.
- Market Saturation: Heavy competition could diminish pricing power.
Opportunities:
- Orphan Designation: If applicable, grants market exclusivity and premium pricing.
- Expansion of Indications: Broader label approvals increase patient populations and revenue.
Key Takeaways
- Initial high prices ($80K–$120K/year) are anticipated, driven by the drug’s therapeutic impact, manufacturing complexity, and patent protections.
- Market entry of biosimilars around years 4–7 is likely to induce significant price reductions, potentially 25–40%, aligning with observed biologic market trends.
- Patent expirations and competitive pressures will be primary factors in long-term price erosion, with possible stabilization above $50,000/year if used in expanded indications or specialty niches.
- Strategic positioning, like orphan drug status or exclusive indications, can sustain premium prices longer-term.
- Reimbursement negotiations and real-world evidence supporting superior efficacy can bolster pricing strategies and market share.
FAQs
Q1: How does the regulatory status of NDC 00641-6045 influence its pricing?
Full FDA approval typically allows for higher pricing due to assured efficacy and safety. Accelerated approval may limit initial pricing premium but can facilitate faster market entry. Regulatory exclusivities also support sustained high prices.
Q2: What are the main competitive threats to this drug’s pricing?
Introduction of biosimilars, generic alternatives, or new therapies with superior efficacy can significantly reduce prices and market share.
Q3: How do payer tactics impact the final net price?
Rebates, discounts, and formulary placements negotiated with payers can lower net prices by 20–30%, even if list prices remain high.
Q4: How important is indication expansion for the long-term pricing?
Expanding indications increases the patient population, justifies higher prices, and extends market exclusivity, supporting revenue continuity.
Q5: When can stakeholders expect significant price erosion?
Typically after patent expiry, approximately 8–10 years post-launch, with biosimilar competition and market saturation leading to 25–40% price reductions over subsequent years.
Sources
- IQVIA, The Impact of Biosimilars on Pricing and Market Dynamics, 2022.
- U.S. Food and Drug Administration, Biologics Price Competition and Innovation Act (BPCIA), 2010.
- EvaluatePharma, Global Oncology Market Forecast, 2023.
- Centers for Medicare & Medicaid Services, Drug Pricing and Reimbursement Policies, 2022.
- ICONIC Data, Biologics Pricing Trends in the United States, 2023.
Disclaimer: All projections are estimates based on current market data and trends. Actual pricing and market conditions may vary with future regulatory, clinical, and competitive developments.
More… ↓
